Randomized phase 3 studies of AURA3 and FLAURA demonstrated that osimertinib is indicated as the first-line treatment for metastatic patients with NSCLC having EGFR sensitizing mutations and for patients with metastatic NSCLC having EGFR T790M mutations whose disease has progressed or after the treatment with first- or second-generation EGFR TKI (5, 6). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.